Cellares
- Industry
- Biotechnology
- Founded Year
- 2019
- Headquarters
- South San Francisco, CA
- Employee Count
- 0
Key People
- Fabian Gerlinghaus - Co-founder and CEO
- Omar Kurdi - Co-founder
- Alex Morgan - Co-founder
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The founding team comprises experienced entrepreneurs with successful backgrounds in MedTech.
The co-founders have previously led successful ventures in the MedTech space, bringing valuable experience and industry connections to Cellares.
- Clinical Need
-
Aspect: Very Strong
Summary: Cellares addresses a critical bottleneck in cell therapy manufacturing, enhancing scalability and efficiency.
With the cell therapy market projected to grow significantly, Cellares' automated manufacturing platform is essential for scaling production to meet patient needs.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has several players, but Cellares' automation technology offers a competitive edge.
The cell therapy manufacturing sector includes multiple companies; however, Cellares' Cell Shuttle system provides a unique value proposition through automation and scalability.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing and implementing automated manufacturing systems involves moderate technical challenges.
While automation in cell therapy manufacturing is complex, Cellares' experienced team and strategic partnerships mitigate these challenges effectively.
- Patent
-
Aspect: Strong
Summary: Cellares holds strong intellectual property rights for its Cell Shuttle technology.
The company's proprietary technology is well-protected, ensuring market exclusivity and potential for licensing opportunities.
- Financing
-
Aspect: Well-funded
Summary: Cellares has secured substantial funding, including a $255 million Series C round.
The significant investment reflects investor confidence and provides the capital necessary for scaling operations and entering new markets.
- Regulatory
-
Aspect: 510k/PMA
Summary: Cellares' manufacturing platform aligns with regulatory standards for cell therapy production.
The company's focus on meeting FDA and other regulatory guidelines ensures the safety and efficacy of its manufacturing processes, crucial for client trust and product approval.
Opportunity Rollup
- Odds of Success
- 3.4
- Peak Market Share
- 4.3
- Segment CAGR
- 11.5%
- Market Segment
- Cell Therapy Manufacturing
- Market Sub Segment
- Automated Manufacturing Platforms
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.64 |
| 3 | 1.50 |
| 4 | 3.01 |
| 5 | 4.30 |
Key Takeaway
Cellares is well-positioned to capitalize on the growing demand for efficient cell therapy manufacturing through its innovative automation solutions and strong industry partnerships.